Oric Pharmaceuticals Announces Development Plans, Cash Runway, and Milestones
ORIC Pharmaceuticals announced focused development plans for its lead programs, ORIC-944 and ORIC-114, extending its cash runway into 2027....
FDA Accepts Medincell and Teva Uzedy for Bipolar I Disorder Treatment
Teva Pharmaceuticals and Medincell announced that the FDA accepted their supplemental New Drug Application for UZEDY, a long-acting injectable...
Elixirgen Therapeutics First Gene Therapy Trial Shows Telomere Elongation
Elixirgen Therapeutics announced positive Phase 1/2 clinical trial data for EXG-34217, a novel therapy for Telomere Biology Disorders (TBDs)....
Trethera & UCLA Publish Data on TRE-515 in Mice with MS
Trethera Corporation announced research published in Immunology demonstrating that their drug, TRE-515, effectively inhibits the hyperactive lymphocytes responsible for...
FemBloc Permanent Birth Control: Positive Safety and Efficacy Results
Femasys Inc. announced positive clinical trial data for FemBloc, a non-surgical permanent birth control method, published in the Journal...
Silexion Announces Promising Pancreatic Cancer Study Results
Silexion Therapeutics (NASDAQ: SLXN) has completed data collection for its first study of SIL-204 in orthotopic pancreatic cancer models....
Ampligen and Imfinzi in Phase 2 Pancreatic Cancer Trial
AIM ImmunoTech has dosed the first patient in Phase 2 of its Phase 1b/2 clinical trial, DURIPANC, evaluating Ampligen...
Alzamend Neuro Starts Phase 2 Trial of AL001 at Mass General
Alzamend Neuro plans to initiate the first of five Phase II clinical trials for AL001, a novel lithium-delivery system,...
Candel Therapeutics Announces Positive CAN-2409 Trial Data
Candel Therapeutics announced positive final overall survival data from its Phase 2 trial of CAN-2409 in patients with borderline...
Ensuring Data Security Throughout the Trial Lifecycle
Clinical trials rely on robust data security measures to protect sensitive participant information, including personally identifiable information (PII) and...